Clinical trial Recruiting at 1 site Interventional Ages 18 and up Women only

Using a reminder app to improve skin care for breast cancer patients during radiation therapy

Official title: Dermatitis During Adjuvant Irradiation for BREAst Cancer: Grade ≥2 Radiation Dermatitis in Breast Cancer Patients with or Without a Mobile Application (Reminder-App)

Run by University Hospital Schleswig-Holstein · NCT06483477 · Data updated 2026-11-12

This study tests if a reminder app can help breast cancer patients take better care of their skin during radiation therapy and reduce skin problems.

More Breast Cancer Female trials

Quick facts

Study typeInterventional
Ages18 Years and up
SexWomen only
Enrollment268 (estimated)
SponsorUniversity Hospital Schleswig-Holstein
Academic / other
Drugs / interventionsradiation
Locations5 sites (Vejle, Southern Denmark and 4 other locations)
StatusRecruiting
StartedDecember 23, 2024
Main results expectedSeptember 30, 2026
Study endsSeptember 30, 2026
Registry record updatedJanuary 16, 2025
Trial IDNCT06483477 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are female patients aged 18 and older with histologically proven invasive breast cancer who are scheduled for adjuvant radiotherapy and can use a smartphone.

Probably not a fit

Patients who are pregnant, lactating, or expected to be non-compliant with the treatment protocol may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This trial evaluates the effectiveness of a reminder app designed to prompt breast cancer patients to perform necessary skin care routines during adjuvant radiotherapy. A total of 268 patients will be randomly assigned to either receive standard skin care with the app or standard skin care alone. The primary goal is to determine if the app can reduce the incidence of grade ≥2 radiation dermatitis. Secondary objectives include assessing pain levels, patient satisfaction with the app, and the app's impact on health technology usage.

Why it matters

Potential benefit: If successful, this approach could significantly reduce the severity of radiation dermatitis in breast cancer patients undergoing treatment.

How similar studies have gone: While the use of mobile applications in healthcare is growing, this specific approach to managing radiation dermatitis is relatively novel and has not been extensively tested in previous studies.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Histologically proven invasive breast cancer
2. Indication for adjuvant hypo-fractionated radiotherapy
3. Possession of and ability to use a smartphone
4. Female gender
5. Age ≥18 years
6. Written informed consent
7. Capacity of the patient to contract

Exclusion Criteria:

1. Pregnancy, Lactation
2. Expected non-compliance

Where it's running

  • Department of Radiation Oncology, University of Lübeck and University Medical Center Schleswig-Holstein
    Lübeck, Germany
    Recruiting
  • Vejle Hospital, University Hospital of Southern Denmark
    Vejle, Southern Denmark, Denmark
    Not yet recruiting
  • Medical Practice for Radiotherapy and Radiation Oncology
    Hanover, Lower Saxony, Germany
    Not yet recruiting
  • Medical School Hamburg, Schwerin Campus
    Schwerin, Mecklenburg-Vorpommern, Germany
    Not yet recruiting
  • Malteser Hospital St. Franziskus
    Flensburg, Schleswig-Holstein, Germany
    Not yet recruiting

Study contacts

  • Principal investigator: Dirk Rades, MD, FASTRO — Dept. of Radiation Oncology, University of Lubeck, Germany
  • Study coordinator: Dirk Rades, MD, FASTRO
  • Email: DIRK.RADES@UKSH.DE
  • Phone: 0049-451-500

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.